PloS one

The Journal of organic chemistry

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Chemical communications (Cambridge, England)

BMC infectious diseases

Lancet (London, England)

The American journal of tropical medicine and hygiene

przeglad epidemiologiczny

genome medicine

drug development research

the indian journal of tuberculosis

journal of chemotherapy (florence, italy)

[1] Cost effectiveness of decentralised care model for managing MDR-TB in India.

[2] Diagnosis of tuberculosis from smear-negative presumptive TB cases using Xpert MTB/Rif assay: a cross-sectional study from Nepal.

[3] Use of GeneXpert and the role of an expert panel in improving clinical diagnosis of smear-negative tuberculosis cases.

[4] A cross-sectional study of tuberculosis drug resistance among previously treated patients in a tertiary hospital in Accra, Ghana: public health implications of standardized regimens.

[5] Opportunities and challenges of using five-membered ring compounds as promising antitubercular agents.

[6] A rhodium(ii) catalysed domino synthesis of azepino fused diindoles from isatin tethered N-sulfonyl-1,2,3-triazoles and indoles.

[7] The molecular patterns of resistance to anti-tuberculosis drugs: an analysis from Istanbul, Turkey.

[8] MDR/XDR-TB management of patients and contacts: challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network.

[9] applicability of the shorter ‘bangladesh regimen’ in high multidrug-resistant tuberculosis settings

[10] mdr-tb in belarus, the role of outpatient care strengthening and social support

[11] systematic evaluation of structure-activity relationships of the riminophenazine class and discovery of a c2 pyridylamino series for the treatment of multidrug-resistant tuberculosis

[12] uji kepekaan obat anti tuberkulosis lini kedua menggunakan bactec mycobacterium growth indicator tubes (mgit) 960

[13] cellular therapy in tuberculosis

[14] Prospective evaluation of simply modified MODS assay: an effective tool for TB diagnosis and detection of MDR-TB

[15] Prospective evaluation of simply modified MODS assay: an effective tool for TB diagnosis and detection of MDR-TB

[16] Comparison of Serum Potassium, MagnEsium, and Calcium Levels between Kanamycin and Capreomycin-BASEd Regimen-Treated MultiDrug-Resistant TuBerculosis Patients in Bandung (CEASE MDR-TB): A Retrospective Cohort Study

[17] Risk Factors of Gout in MDR-TB Patients in Eritrea: A Case-Control Study

[18] Frequency and patterns of second-line resistance conferring mutations among MDR-TB isolates resistant to a second-line drug from eSwatini, Somalia and Uganda (2014-2016).

[19] The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.

[20] Epidemiology of MDR-TB in a belgian infectious diseases unit: A 15 years review

[21] Multidrug-resistant tuberculosis (MDR-TB): Epidemiology, mechanisms of drug resistance

[22] Multidrug-resistant tuberculosis (MDR-TB): Epidemiology, prevention and treatment

[23] Factors Affecting the Success of Multi Drug Resistance (MDR-TB) Tuberculosis Treatment in Residential Surakarta

[24] Cost effectiveness of decentralised care model for managing MDR-TB in India.

[25] Epidemiology of Multidrug Resistant Tuberculosis (MDR-TB)

[26] GeneXpert MTB/RIF is superior to BBD max MDR-TB for diagnosis of tuberculosis (TB) in a country with low incidence of multidrug-resistant TB (MDR-TB)

[27] Prevalence of Pre-Extensively Drug-Resistant Tuberculosis (Pre XDR-TB) and Extensively Drug-Resistant Tuberculosis (XDR-TB) among pulmonary Multidrug Resistant Tuberculosis (MDR-TB) at a tertiary care center in Mumbai

[28] The Impact of Concurrent Antiretroviral Therapy and MDR-TB Treatment on Adverse Events.

[29] MDR-TB Outbreak among HIV-Negative Tunisian Patients followed during 11 Years.

[30] mdr-tb in belarus, the role of outpatient care strengthening and social support

[31] epidemiology and spatial distribution of cases of multidrug-resistant tuberculosis (mdr-tb) in brazil, 2008-2012

[32] Susceptibility testing breakpoints for Mycobacterium tuberculosis categorize isolates with resistance mutations in gyrA as susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TB